Join
Live feed
·
PRReleasevia Quantisnow
Theriva Biologics Inc. logo

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

ByQuantisnow·Wall Street's wire, on your screen.
TOVX· Theriva Biologics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TOVX (Theriva Biologics Inc.) and more on Quantisnow.